FDA advisory panel split over Sanofi-Lexicon diabetes drug
(Reuters) - Independent experts on an FDA advisory panel were equally split when voting on whether to approve an oral treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.
The panel on Thursday voted 8-8 when asked to assess the once-daily oral medicine, sotagliflozin, an add-on treatment to insulin therapy for patients with type 1 diabetes.
The FDA is expected to make a final decision on the drug's approval by March 22.
(Reporting by Saumya Sibi Joseph and Tamara Mathias in Bengaluru)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.